poisar

Stock

Actuate Therapeutics, Inc. ACTU

$1.19-6.67%

Overview

ACTU market data

Price History

ACTU price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$1.06
Diluted earnings per share over the trailing twelve months.
Beta
2.01
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$1.16 – $9.22
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $30.3 · P/B 17.95.

Company news

7 captured
8-K filing — ACTUATE THERAPEUTICS, INC. (ACTU)SEC EDGAR · Jul 17, 2026, 8:30 PM
Actuate Therapeutics shares are trading higher after the company announced that elraglusib will be evaluated in the BEACON2 clinical trial to identify and advance treatment approaches for children with relapsed and refractory neuroblastoma.Benzinga · Jun 9, 2026, 7:52 PM
Actuate Therapeutics' Elraglusib To Be Evaluated In BEACON2 Clinical Study To Identify, Proceed To Treat Children With Relapsed, Refractory NeuroblastomaBenzinga · Jun 9, 2026, 11:55 AM
Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic CancerGlobenewswire Inc · Jun 1, 2026, 11:15 AM
Actuate Therapeutics Features Post-Hoc Efficacy And Biomarker Analyses From Randomized Phase 2 Study, Along With Clinical Data From Phase 2 Study Of Elraglusib In Combination With FFX And TGF-Β Inhibitor Losartan In mPDAC Patients, At 2026 ASCOBenzinga · Jun 1, 2026, 11:07 AM
HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price TargetBenzinga · May 18, 2026, 5:50 PM
Actuate Therapeutics Announces FDA Clearance Of IND For Phase 1/2 Study Of Oral Elraglusib In Advanced Cancer Patients, With Focus On Metastatic Melanoma, NSCLC, Colorectal, And Pancreatic Cancers With Initiation Planned For 2H 2026Benzinga · May 11, 2026, 11:08 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock